|Bid||14.50 x 1000|
|Ask||0.00 x 900|
|Day's Range||15.13 - 16.21|
|52 Week Range||11.38 - 29.61|
|Beta (5Y Monthly)||1.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 02, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.33|
Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will report third quarter 2020 financial results on Monday, November 2, 2020. Karyopharm's management team will host a conference call and audio webcast at 4:30 p.m. ET on Monday, November 2, 2020, to discuss the financial results and other company updates.
MediSpend announced that Karyopharm Therapeutics (NASDAQ: KPTI) selected MediSpend Transparency Solution to comply with state and federal transparency reporting regulations. MediSpend Transparency Solution is a SaaS-based solution that collects, remediates, validates, analyzes and reports transfers of value to comply with state, federal and global transparency laws and codes. Karyopharm Therapeutics was implemented and went live with MediSpend's Transparency Solution in October 2020.